Ascletis Pharma (HKG:1672) said it was looking to raise HK$843.5 million via a share offering, according to a Hong Kong bourse filing Tuesday.
The firm is seeking investors for around 69.3 million shares priced at HK$12.18 apiece to raise funds for the global phase 3 trials of its ASC30 drug for the treatment of obesity.
The shares represent 6.98% of the company's issued share capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments